- Interleukin Inhibitors
- Tumor Necrosis Factor (TNF)
- Others
Plaque Psoriasis Treatment Market size was valued at USD 18.0 billion in 2022 and is poised to grow at a CAGR of 10.0% from 2023 - 2029. As the prevalence of psoriasis rises worldwide, manufacturers are transforming breakthrough research into novel therapies by investing more in research. The number of medications approved for plaque psoriasis is constantly expanding, giving physicians and patients more treatment options. For instance, the FDA approved Eli Lilly's interleukin inhibitor, the second chemical after Novartis' Cosentyx. Companies are conducting various clinical trials and head-on-head trials with existing medications to create biologic therapies that will provide improved therapy alternatives for psoriasis patients. To encourage the acceptance of their breakthrough treatments, companies are increasingly offering co-pay choices to patient. According to the World Psoriasis Day consortium, psoriasis affects 125 million individuals worldwide. Novel systemic therapies using a variety of biologics are now being introduced. For instance, In April 2019, Ortho Dermatologics stated that an FDA-approved lotion for the treatment of psoriasis patients had been approved. The use of 'Duobrii' to treat plaque psoriasis has been authorized. Adults with plaque psoriasis will benefit from the product. In tandem with Duobrii to treat other significant psoriasis disorders, several efforts are being made to develop new products. The primary focus of the companies is on EU-5 and US countries to market the drugs. However, psoriasis incidence is higher in European countries like Netherlands, Norway, Denmark, and Austria and in Asia Pacific countries like China, Japan, and India. The expansion of the marketing of psoriasis drugs in these countries might provide an opportunity for the manufacturers to generate additional revenues. Celgenes Otezla was launched in Germany, Switzerland, Austria, Scotland, and certain Scandinavian countries; the growth is expected from the expansion of the launch of OTEZLA in Europe and Japan markets, where it is well-positioned to repeat the success that is realized in the U.S. market.
Plaque Psoriasis Treatment Market Key Developments:
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The increasing prevalence of psoriasis conditions globally is projected to drive the sales of psoriasis drugs over the forecast period. Furthermore, an increase in awareness about the psoriasis conditions and active participation of non-profit organizations to bring awareness among psoriasis patients about the new therapies are expected to drive the plaque psoriasis market. On the other hand, the primary factor restraining the growth of the psoriasis market is the high cost of the drugs. Due to the drug’s higher price, the drugs are not affordable for all patients, and it has had a negative impact on the sales of the psoriasis drug market.
The plaque psoriasis treatment market is projected to expand at a CAGR of 10.0% during the forecast period.
Novartis AG (Switzerland), AbbVie Inc.(U.S), Amgen, Inc. (U.S), Johnson & Johnson (U.S), Eli Lilly and Company (U.S)
North America is the fastest-growing region for plaque psoriasis treatment market
1. Executive Summary |
2. Global Plaque Psoriasis Treatment Market Introduction |
2.1.Global Plaque Psoriasis Treatment Market - Taxonomy |
2.2.Global Plaque Psoriasis Treatment Market - Definitions |
2.2.1.Product Type |
2.2.2.Distribution Channel |
2.2.3.Region |
3. Global Plaque Psoriasis Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Plaque Psoriasis Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Plaque Psoriasis Treatment Market By Product Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Interleukin Inhibitors |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Tumor Necrosis Factor (TNF) |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Others |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Plaque Psoriasis Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Hospital Pharmacies |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Retail Pharmacies |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Others |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Plaque Psoriasis Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8. North America Plaque Psoriasis Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Interleukin Inhibitors |
8.1.2.Tumor Necrosis Factor (TNF) |
8.1.3.Others |
8.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospital Pharmacies |
8.2.2.Retail Pharmacies |
8.2.3.Others |
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9. Europe Plaque Psoriasis Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Interleukin Inhibitors |
9.1.2.Tumor Necrosis Factor (TNF) |
9.1.3.Others |
9.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospital Pharmacies |
9.2.2.Retail Pharmacies |
9.2.3.Others |
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
10. Asia Pacific (APAC) Plaque Psoriasis Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Interleukin Inhibitors |
10.1.2.Tumor Necrosis Factor (TNF) |
10.1.3.Others |
10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospital Pharmacies |
10.2.2.Retail Pharmacies |
10.2.3.Others |
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11. Middle East and Africa (MEA) Plaque Psoriasis Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Interleukin Inhibitors |
11.1.2.Tumor Necrosis Factor (TNF) |
11.1.3.Others |
11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospital Pharmacies |
11.2.2.Retail Pharmacies |
11.2.3.Others |
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12. Latin America Plaque Psoriasis Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Interleukin Inhibitors |
12.1.2.Tumor Necrosis Factor (TNF) |
12.1.3.Others |
12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospital Pharmacies |
12.2.2.Retail Pharmacies |
12.2.3.Others |
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Allergan |
13.2.2.Johnson and Johnson |
13.2.3.Amgen |
13.2.4.Abbvie |
13.2.5.Eli Lilly |
13.2.6.Dermira Inc. |
14. Research Methodology |
15. Appendix and Abbreviations |